Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

Medtronic Plc
MDT - NYSE - $101.80 (as of ) ▼ -2.90%
-
Earnings Tue 24 Nov

Medtronic opens the
books on Tuesday evening.

The median of 10 price targets is $971, stock is $102, -4.7% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
B+
Council 2/6 - Historical V1 score 57

B+ — FMP rating1.

Quick Answer

Q2 consensus: revenue $9.5B1, EPS $1.331. Thierry Pieton guided Cardiac Ablation Solutions to 11.5-12% (previous 6.6%) in the Q4 earnings call2. 8 consecutive quarters of beat1.

$1.33 EPS Estimate Last year $1.36 - -2% YoY
12% Cardiac Ablation Solutions Guidance Previous quarter was 6.6%
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 FY27 EPS $1.45 vs $1.39 estimate: beat (+4.3%)1. Stock move on the next trading day: +0.2%1.

Next report

What to watch in Q2 FY27 (Nov 24, 2026)

  • EPS: consensus $1.33, against $1.36 in the same quarter a year ago (-2%).
  • Revenue: consensus $9.5B.

Watchlist

6 metrics stand out this quarter.

6.75% Expectation / Guide

Fy27 Revenue Guidance

Medtronic guides FY27 organic revenue growth of 6.75% to 7.25%, with approximately 11.5% to 12% in the first quarter.

Thierry Pieton, CFO - Q4 FY26 Earnings Call - June 3, 2026
78% Investor Focus

Cas Growth Share Gain

Cardiac Ablation Solutions grew 78% worldwide in Q4 while gaining 8 additional points of U.S. share.

Geoffrey Martha, Chairman and CEO - Q4 FY26 Earnings Call - June 3, 2026
$5.90 Expectation / Guide

Fy27 Eps Guidance

The company guided FY27 EPS of $5.90 to $6.00.

Thierry Pieton, CFO - Q4 FY26 Earnings Call - June 3, 2026
$2 billion Investor Focus

M And A Venture Investment

Medtronic closed or announced nearly $2 billion of additional investments in Q4 under its M&A and venture capital strategy.

Thierry Pieton, CFO - Q4 FY26 Earnings Call - June 3, 2026
$250 million Investor Focus

Tariff Impact Fy27

The company expects a total FY27 tariff impact to COGS of approximately $250 million, including $75 million in the first quarter.

Thierry Pieton, CFO - Q4 FY26 Earnings Call - June 3, 2026
$100 million Investor Focus

Symplicity Renal Denervation

Symplicity renal denervation has accelerated since the NCD and is now annualizing at $100 million.

Geoffrey Martha, Chairman and CEO - Q4 FY26 Earnings Call - June 3, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ken Griffin, Buffett), 2 bearish (Klarman, Munger), 2 neutral (Ray Dalio, Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside -4.7%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 64
Klarman value - target upside -4.7%
Buffett quality - ROE score 4/5
Munger valuation - target upside -4.7%
Munger's Mindset character & balance sheet lens
Overvalued

Quality business, but price is high.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
63.8 RSI 63.8 positive momentum, 50d above
MACD
+9.80 price above 50d - support positive
50d MA
$93 stock 9.8% above - short-term support
200d MA
$88 stock 15.4% above - long-term support
Volume (10d)
-15% decrease - low participation
Resistance
$97
Analyst median target - upgrade trigger if broken
Current
$102
Pre-earnings position
Support
$75
Invalidation - close below this is a technical breakdown
Pattern
Range
$75-$97 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q2 FY26
$1.36 vs $1.31 est · Next-day price move: -0.5%
BEAT
Q3 FY26
$1.36 vs $1.34 est · Next-day price move: +2.2%
BEAT
Q4 FY26
$1.55 vs $1.54 est · Next-day price move: +5.1%
BEAT
Q1 FY27
$1.45 vs $1.39 est · Next-day price move: +0.2%

Q1 FY27 (September 1, 2026) EPS $1.45 vs $1.39 estimate: beat (+4.3%)1.

Three scenarios: what could happen?

Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

Insider trading signal

Form 4 Q1 FY27: 6 transactions, net -$6.48M1.

Executive Action Amount Date
Marinaro Michael EVP, Pres MedSurg and Americas Sale -$1.00M 2026-10-16
Martha Geoffrey director, Chairman and CEO Sale -$4.75M 2026-10-16
KIIL HARRY SKIP EVP & President Cardiovascular Sale -$138.9K 2026-09-17
Walter Matthew R. SVP, Chief HR Officer Sale -$257.9K 2026-07-09
KIIL HARRY SKIP EVP & President Cardiovascular Sale -$318.6K 2026-06-09
KIIL HARRY SKIP EVP & President Cardiovascular Sale -$18.3K 2026-06-09

6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $130.2B market cap.

CapEx shock

Q4 CapEx $503.0M1. Q4 op margin 18.1%1 - this level in Q2 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q2 EPS > $1.33 + Cardiac Ablation Solutions >= 12%
Threshold: EPS > $1.331 and Cardiac Ablation Solutions >= 12%2.
Target: Break above median target $971; high target $1151 upper bound.
Scenario B - In-Line
EPS approx $1.33 + Cardiac Ablation Solutions 11.5-12%
Threshold: EPS approx $1.331, Cardiac Ablation Solutions 11.5-12%, Q2 CapEx < $503.0M1.
Target: Consolidation in the band between current $1021 and median $971.
Scenario C - Miss
EPS < $1.29 or Cardiac Ablation Solutions < 35% or CapEx >= $503.0M
Threshold: EPS < $1.291 or Cardiac Ablation Solutions < 35%2.
Current price $102 — above SMA200 $881.

Market Outlook

What do analysts say? 10 price targets · 30 ratings

Wall Street Consensus
$97
12-month median target price (-4.7% gap to the analyst consensus median)
20
BUY
10
HOLD
0
SELL
Risk Management
$75
Invalidation level - critical support threshold
$93 - 50-day MA (above, +9.8%)
$88 - 200-day MA (above, +15.4%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - MDT Q2 FY27
B+

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q2 EPS threshold $1.331, Cardiac Ablation Solutions guidance 11.5-12%2, CapEx threshold "below $503.0M". Three anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Nov 24, 2026EARNINGSQ2 FY27 results (after market close) + earnings call
Nov 25, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Dec 10, 2026 – Dec 15, 2026FILING10-Q due within 40–45 days of quarter end (by Dec 10, 2026 – Dec 15, 2026); the exact deadline depends on filer status
~Feb 24, 2027EARNINGSQ3 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the MDT Q2 FY27 earnings preview cover?

This Medtronic plc (MDT) Q2 FY27 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in MDT Q2 FY27 earnings?

Medtronic plc (MDT): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Medtronic plc (MDT): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

Medtronic plc (MDT): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded